Aging · 2023 · 16 citations · 40 references
MedicinePharmacologyToxicologyBiochemical PharmacologyCancer PharmacologyChemotherapyAnthracycline CardiotoxicityCancer Therapy-related CardiotoxicityCardiotoxicity ManagementCardiovascular DiseaseMechanisms Of Toxic InjuryMitochondrial ToxicityCardiac Mitochondrial FunctionCardioprotective TherapyCardiotoxicityCardiotoxicity MitigationChemotherapeutic ToxicologyDoxorubicin CardiotoxicityMechanisms Of Cardiac InjuryTraditional Chinese Medicine
Doxorubicin (DOX) is a potent chemotherapeutic drug used for treating various cancers. However, its clinical use is limited due to its severe cardiotoxicity, which often results in high mortality rates. Sheng-Mai-Yin (SMY), a Traditional Chinese medicine (TCM) prescription, has been reported to exert a cardioprotective effect in various cardiovascular diseases, including DOX-induced cardiotoxicity (DIC). This study aimed to provide novel insights into the underlying cardioprotective mechanism of SMY. SMY, composed of Codonopsis pilosula (Franch.), Ophiopogon japonicus (Thunb.), and Schisandra chinensis (Turcz.) at a ratio of 3:2:1, was intragastrically administered to male C57BL/6 mice for five days prior to the intraperitoneal injection of mitoTEMPO. One day later, DOX was intraperitoneally injected. Hematoxylin-eosin staining and Sirius red staining were carried out to estimate the pharmacological effect of SMY on cardiotoxicity. Mitochondrial function and ferroptosis biomarkers were also examined. AAV was utilized to overexpress Hmox1 to confirm whether Hmox1-mediated ferroptosis is associated with the cardioprotective effect of SMY on DOX-induced cardiotoxicity. The findings revealed that SMY therapy reduced the number of damaged cardiomyocytes. SMY therapy also reversed the inductions of cardiac MDA, serum MDA, LDH, and CK-MB contents, which dramatically decreased nonheme iron levels. In the meantime, SMY corrected the changes to ferroptosis indices brought on by DOX stimulation. Additionally, Hmox1 overexpression prevented SMY's ability to reverse cardiotoxicity. Our results showed that SMY effectively restrained lipid oxidation, reduced iron overload, and inhibited DOX-induced ferroptosis and cardiotoxicity, possibly via the mediation of Hmox1.
40
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Scott J. Dixon, Kathryn M. Lemberg, Michael R. Lamprecht et al. · Cell · 2012 · 18.1K citations · Full text
Regulation of Ferroptotic Cancer Cell Death by GPX4
Wan Seok Yang, Rohitha Sriramaratnam, Matthew Welsch et al. · Cell · 2014 · 7.5K citations · Full text
Congestive heart failure in patients treated with doxorubicin
Sandra M. Swain, Fredrick S. Whaley, Michael S. Ewer · Cancer · 2003 · 2.3K citations · Full text
Medicine, Oncology, Pharmacology +15
Ferroptosis as a target for protection against cardiomyopathy
Xuexian Fang, Hao Wang, Dan Han et al. · Proceedings of the National Academy of Sciences · 2019 · 2.1K citations · Full text
Role of Mitochondria in Ferroptosis
Minghui Gao, Jun-Mei Yi, Jiajun Zhu et al. · Molecular Cell · 2018 · 2.1K citations · Full text